A new study published in the journal Acta Neuropsychiatrica<\/i> indicates that transcranial direct current stimulation (tDCS) significantly improves non-motor symptoms\u2014specifically depression and apathy\u2014in patients with Parkinson’s disease. Conducted by researchers at the Korea University College of Medicine, the study is particularly notable for integrating wearable technology to objectively monitor clinical outcomes in real-world settings.<\/p>\n
Parkinson’s disease is a progressive neurodegenerative disorder characterized not only by traditional motor symptoms (tremors, rigidity, and bradykinesia) but also by non-motor manifestations such as depression, anxiety, and apathy. These psychoemotional factors severely impair patients’ quality of life and hinder effective disease management. Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation therapy that regulates neuronal activity in targeted brain regions by delivering low-intensity electrical currents through electrodes placed on the scalp. Because the procedure requires no surgical intervention or anesthesia and involves minimal discomfort, it is considered a safe alternative for managing emotional and cognitive symptoms.<\/p>\n
The study enrolled 20 patients diagnosed with Parkinson’s disease who exhibited depressive symptoms. Over several weeks, participants underwent 10 tDCS sessions (three times per week) targeted at brain regions responsible for emotional regulation. Concurrently, patients wore smart bands that continuously tracked their daily physical activity (step counts) and sleep patterns.<\/p>\n
The data demonstrated marked improvements following treatment:<\/p>\n
Depressive symptoms<\/b> decreased by approximately 54%<\/b>;<\/p>\n<\/li>\n Anxiety<\/b> was reduced by 38%<\/b>;<\/p>\n<\/li>\n Apathy<\/b> (loss of motivation and interest) improved by 25%<\/b>;<\/p>\n<\/li>\n Motor symptoms<\/b> eased by approximately 35%<\/b>.<\/p>\n<\/li>\n<\/ul>\n Importantly, these clinical gains translated into measurable changes in daily life. Wearable device data confirmed a significant increase in spontaneous daytime physical activity post-therapy, indicating that patients became more active outside the clinic environment.<\/p>\n The researchers identified apathy reduction\u2014rather than the direct alleviation of depression\u2014as the strongest predictor of increased daily physical activity. Restored motivation directly correlated with physical engagement, a link that remained consistent regardless of patient age or disease duration.<\/p>\n According to the authors, the study demonstrates that non-invasive brain stimulation holds potential as a safe and effective adjunctive therapy. Furthermore, integrating smart wearable devices into clinical practice enables clinicians to objectively evaluate patient outcomes in natural environments rather than relying solely on in-clinic visits, paving the way for personalized treatment strategies in the future.<\/p>\nReduced Apathy as a Key Driver of Physical Activity<\/h3>\n